214 related articles for article (PubMed ID: 37549269)
21. LSD1 dual function in mediating epigenetic corruption of the vitamin D signaling in prostate cancer.
Battaglia S; Karasik E; Gillard B; Williams J; Winchester T; Moser MT; Smiraglia DJ; Foster BA
Clin Epigenetics; 2017; 9():82. PubMed ID: 28811844
[TBL] [Abstract][Full Text] [Related]
22. Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer.
Tam KJ; Liu L; Hsing M; Dalal K; Thaper D; McConeghy B; Yenki P; Bhasin S; Peacock JW; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
Sci Rep; 2024 Mar; 14(1):7082. PubMed ID: 38528115
[TBL] [Abstract][Full Text] [Related]
23. Targeting INMT and interrupting its methylation pathway for the treatment of castration resistant prostate cancer.
Zhong S; Jeong JH; Huang C; Chen X; Dickinson SI; Dhillon J; Yang L; Luo JL
J Exp Clin Cancer Res; 2021 Sep; 40(1):307. PubMed ID: 34587977
[TBL] [Abstract][Full Text] [Related]
24. FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A.
Wang X; Brea L; Lu X; Gritsina G; Park SH; Xie W; Zhao JC; Yu J
Oncogene; 2022 Sep; 41(37):4259-4270. PubMed ID: 35931888
[TBL] [Abstract][Full Text] [Related]
25. SETD7 Drives Cardiac Lineage Commitment through Stage-Specific Transcriptional Activation.
Lee J; Shao NY; Paik DT; Wu H; Guo H; Termglinchan V; Churko JM; Kim Y; Kitani T; Zhao MT; Zhang Y; Wilson KD; Karakikes I; Snyder MP; Wu JC
Cell Stem Cell; 2018 Mar; 22(3):428-444.e5. PubMed ID: 29499155
[TBL] [Abstract][Full Text] [Related]
26. Substrate docking-mediated specific and efficient lysine methylation by the SET domain-containing histone methyltransferase SETD7.
Liu H; Li Z; Yang Q; Liu W; Wan J; Li J; Zhang M
J Biol Chem; 2019 Sep; 294(36):13355-13365. PubMed ID: 31324717
[TBL] [Abstract][Full Text] [Related]
27. Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics.
Chianese U; Papulino C; Passaro E; Evers TM; Babaei M; Toraldo A; De Marchi T; Niméus E; Carafa V; Nicoletti MM; Del Gaudio N; Iaccarino N; Randazzo A; Rotili D; Mai A; Cappabianca S; Mashaghi A; Ciardiello F; Altucci L; Benedetti R
Mol Metab; 2022 Oct; 64():101561. PubMed ID: 35944897
[TBL] [Abstract][Full Text] [Related]
28. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
Krause WC; Shafi AA; Nakka M; Weigel NL
Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967
[TBL] [Abstract][Full Text] [Related]
29. FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway.
Imamura Y; Sakamoto S; Endo T; Utsumi T; Fuse M; Suyama T; Kawamura K; Imamoto T; Yano K; Uzawa K; Nihei N; Suzuki H; Mizokami A; Ueda T; Seki N; Tanzawa H; Ichikawa T
PLoS One; 2012; 7(8):e42456. PubMed ID: 22879989
[TBL] [Abstract][Full Text] [Related]
30. Molecular basis for substrate recognition by lysine methyltransferases and demethylases.
Del Rizzo PA; Trievel RC
Biochim Biophys Acta; 2014 Dec; 1839(12):1404-15. PubMed ID: 24946978
[TBL] [Abstract][Full Text] [Related]
31. CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies.
Hwang JH; Arafeh R; Seo JH; Baca SC; Ludwig M; Arnoff TE; Sawyer L; Richter C; Tape S; Bergom HE; McSweeney S; Rennhack JP; Klingenberg SA; Cheung ATM; Kwon J; So J; Kregel S; Van Allen EM; Drake JM; Freedman ML; Hahn WC
Elife; 2022 May; 11():. PubMed ID: 35550030
[TBL] [Abstract][Full Text] [Related]
32. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J
Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448
[TBL] [Abstract][Full Text] [Related]
33. Lysine N-methyltransferase SETD7 promotes bladder cancer progression and immune escape via STAT3/PD-L1 cascade.
Lv J; Wu Q; Li K; Bai K; Yu H; Zhuang J; Sun H; Yang H; Yang X; Lu Q
Int J Biol Sci; 2023; 19(12):3744-3761. PubMed ID: 37564199
[No Abstract] [Full Text] [Related]
34. Emerging roles of lysine methylation on non-histone proteins.
Zhang X; Huang Y; Shi X
Cell Mol Life Sci; 2015 Nov; 72(22):4257-72. PubMed ID: 26227335
[TBL] [Abstract][Full Text] [Related]
35. The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion.
Wang J; Yu Q; Qiu Z; Dai T; Wang S; Yang X; Evers BM; Wu Y
Aging (Albany NY); 2020 Jan; 12(1):397-415. PubMed ID: 31901895
[TBL] [Abstract][Full Text] [Related]
36. Transcriptomic Analysis of Histone Methyltransferase Setd7 Knockdown and Phenethyl Isothiocyanate in Human Prostate Cancer Cells.
Wang C; Sargsyan D; Zhang C; Wu R; Yang Y; Kong AN
Anticancer Res; 2018 Nov; 38(11):6069-6083. PubMed ID: 30396921
[TBL] [Abstract][Full Text] [Related]
37. FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells.
Guo W; Keener AL; Jing Y; Cai L; Ai J; Zhang J; Fisher AL; Fu G; Wang Z
Prostate; 2015 Jun; 75(9):976-87. PubMed ID: 25808853
[TBL] [Abstract][Full Text] [Related]
38. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
[TBL] [Abstract][Full Text] [Related]
39. Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer.
Helminen L; Huttunen J; Tulonen M; Aaltonen N; Niskanen EA; Palvimo JJ; Paakinaho V
Nucleic Acids Res; 2024 Jan; 52(2):625-642. PubMed ID: 38015476
[TBL] [Abstract][Full Text] [Related]
40. FOXA1 antagonizes EZH2-mediated CDKN2A repression in carcinogenesis.
Zhang Y; Tong T
Biochem Biophys Res Commun; 2014 Oct; 453(1):172-8. PubMed ID: 25264199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
